BioVaxys Technology Corp., a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX platform, has executed a binding Letter of Intent with AP Visionaries Inc. of Ontario (APVI) to jointly develop a proprietary DPX formulation to address the need for a therapy to treat or alleviate the potentially life-threatening risk of certain food allergies, namely those triggered by exposure to peanut/tree nuts or eggs. BioVaxys and APVI are c...